AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.
Under this agreement, AstraZeneca will gain access to CSPC's preclinical candidate YS2302018, an oral Lp(a) inhibitor. This drug is aimed at developing a new lipid-lowering therapy and can be used as a standalone or combination treatment for various cardiovascular diseases, including in combination with the oral small molecule PCSK9 inhibitor, AZD0780.
As part of the agreement, CSPC Pharmaceutical Group will receive an upfront payment of $100 million. Additionally, CSPC could receive up to $1.92 billion in development and commercialization milestone payments, alongside tiered royalties.
